Mega Drive-Thru Vaccination Clinic to Offer Additional Dose for Immunocompromised

City of Corpus Christi seal, Public Health logo and County of Nueces seal

CORPUS CHRISTI, TX – The Corpus Christi – Nueces County Public Health District will conduct a mass vaccination event at the American Bank Center (ABC) on Wednesday, August 18, from 9:00 a.m. to 3:00 p.m. This event is for all people in need of COVID-19 vaccinations, including the first and second doses and the newly approved “additional” dose for moderately to severely immunocompromised individuals.

Both mRNA COVID-19 vaccinations, Moderna and Pfizer, will be available at this event while supplies last. All people must register to receive their vaccination at this event. You can register online at www.cctexas.com/coronavirus under “Vaccine Registration.”  During registration, select the Location: American Bank Center – Drive-thru - 9:00 a.m. to 3:00 p.m. and Date: August 18,  2021.

Depending on the demand for the vaccine at tomorrow’s event, the Public Health District may offer an additional clinic on Thursday, August 19.  A decision will be made on Wednesday.

The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices (ACIP) recommends people whose immune systems are moderate or severely compromised receive an additional dose of mRNA COVID-19 vaccine. ACIP’s recommendation includes:

  • People with a range of conditions, such as recipients of organ or stem cell transplants
  • Those with advance or untreated HIV infection
  • Active recipients of treatment for cancer
  • People who are taking some medications that weaken the immune system

It’s important to note that an additional dose is only recommended for moderately or severely immunocompromised individuals. The CDC does not recommend additional doses for any other population at this time. Currently, there are insufficient data to support the use of an additional mRNA COVID-19 vaccine dose after a single-dose Janssen COVID-19 vaccination series in immunocompromised people. The FDA and CDC are actively working to provide guidance on this issue.